Emerging role of adjuvant hormonal therapy

Urology

Volumn 60, Issue 3 SUPPL. 1, 2002, Pages 13-20

  Mcleod, David G ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GOSERELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CASTRATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOLLOW UP; GYNECOMASTIA; HERNIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; INJURY; MASTALGIA; PAIN; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SEXUAL DYSFUNCTION; SURVIVAL; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; WEIGHT GAIN;

EID: 0036755407     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01562-5     Document Type: Article

References (29)

1. C.J. Mettlin G.P. Murphy D.S. Rosenthal The National Cancer Data Base report on prostate cancer carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society Cancer 83 1998 1679 1684
2. A.K. Stewart K.I. Bland L.S. McGinnis Clinical highlights from the National Cancer Data Base 2000 CA Cancer J Clin 50 2000 171 183
3. J.I. Epstein A.W. Partin J. Sauvageot Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up Am J Surg Pathol 20 1996 286 292
4. M. Roach J. Lu M.V. Pilepich Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials Int J Radiat Oncol Biol Phys 47 2000 609 615
5. W.R. Fair M.S. Cookson N. Stroumbakis The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer Memorial Sloan-Kettering Cancer Center results Urology 49 1997 46 55
6. C.R. Pound A.W. Partin M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
7. C.L. Amling M.L. Blute E.J. Bergstralh Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer continued risk of biochemical failure after 5 years J Urol 164 2000 101 105
8. M. Bolla D. Gonzalez P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
9. M. Bolla L. Colette D. Gonzalez Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy a phase III EORTC study Eur J Cancer 35 1999 582 Abstract 266
10. M.V. Pilepich R. Caplan R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavourable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of the Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
11. C.A. Lawton K. Winter K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
12. T. Granfors H. Modig J.-E. Damber Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement a prospective randomized study J Urol 159 1998 2030 2034
13. G.E. Hanks J. Lu M. Machtay RTOG protocol 92-02 a phase III trial of the use of long term androgen suppres-sion following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate Proc Am Soc Clin Oncol 19 2000 327a Abstract 1284
14. E.M. Messing J. Manola M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
15. T. Prayer-Galetti F. Zattoni A. Capizzi Disease-free survival in patients with pathological “C stage” prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment Eur Urol 38 2000 504 Abstract 48
16. R.S. Kirby Recent advances in the medical management of prostate cancer Br J Clin Pract 50 1996 88 93
17. R. Kirby Treatment options for early prostate cancer Urology 52 1998 948 962
18. M.F. Townsend W.H. Sanders R.O. Northway Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma Cancer 79 1997 545 550
19. H.W. Daniell S.R. Dunn D.W. Ferguson Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 2000 181 186
20. T. Hatano Y. Oishi A. Furuta Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer BJU Int 86 2000 449 452
21. P. Iversen I. Melezinek A. Schmidt Nonsteroidal antiandrogens a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function BJU Int 87 2001 47 56
22. P. Iversen C.J. Tyrrell A.V. Kaisary Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer 6.3 years of followup J Urol 164 2000 1579 1582
23. D.G. McLeod Tolerability of nonsteroidal antiandrogens in the treatment of prostate cancer Oncologist 2 1997 18 27
24. P. Iversen Antiandrogen monotherapy indications and results Urology 60 suppl 3A 2002 64 71
25. W.A. See D. McLeod P. Iversen The bicalutamide early prostate cancer program demography Urol Oncol 6 2001 43 47
26. See WA, Wirth MP, McLeod DG, et al : Bicalutamide (‘Casodex’) 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: First analysis of early prostate cancer program. J Urol 2002 (in press).
27. S.A. Liebel Z. Fuks M.J. Zelefsky The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement Int J Radiat Oncol Biol Phys 28 1994 7 16
28. A. Pollack G.K. Zagars V.S. Kavadi Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer Cancer 74 1994 670 678
29. D.G. McLeod P. Iversen Gynecomastia in patients with prostate cancer a review of treatment options Urology 56 2000 713 720